Leading the way with gamma delta T cells

TC BioPharm's mission is to develop and commercialise innovative cell-based products to target disease, improving patient health and Quality of Life

TC BioPharm's mission is to develop and commercialise innovative cell-based products to target disease, improving patient health and Quality of Life

TC BioPharm's mission is to develop and commercialise innovative cell-based products to target disease, improving patient health and Quality of Life

To treat cancer and viral disease

We are currently developing the next generation of safe CAR-T products based on our patent protected, proprietary processes using the clinically proven ImmuniCELL backbone

We are currently developing the next generation of safe CAR-T products based on our patent protected, proprietary processes using the clinically proven ImmuniCELL backbone

We are currently developing the next generation of safe CAR-T products based on our patent protected, proprietary processes using the clinically proven ImmuniCELL backbone

Improving patient health and Quality of Life
Arrow
Arrow
Slider

TC BioPharm Presents at Cell Therapy Conference, Kyoto

1 MAR 2018

TC BioPharm Presents at CAR-TCR Summit, London

21 FEB 2018

21 Feb 2018

21 FEB 2018

TC BioPharm Opens First Overseas Office in Japan

14 FEB 2018

TC BioPharm Announces Strategic Collaboration with the NIPRO Corporation

7 FEB 2018

TC BioPharm Announces Strategic Collaboration with bluebird bio

7 Dec 2017

TC BioPharm Announces CAR-T Licensing Deal With UCL Business

6 Sep 2017

TCB Selected For EU Horizon 2020 Funding to Progress Novel, Mass-Market Cell Therapies to Clinical Trial

2 Aug 2017

TCB wins Entrepreneurial Business Leadership Award

2 Feb 2017

TCB raises over £6m for innovative cancer treatments

31 Jan 2017

Arrow
Arrow
1
2
3
4
5
6
7
8
9
Slider

Our Platforms

Cell Therapy

Cell Therapy

Autologous and allogeneic Gamma Delta T cell therapies

Genetic Engineering

Genetic Engineering

Modifying Gamma Delta T cells to express target-specific CARs and TCRs

Universal Donor Stem Cells

Universal Donor Stem Cells

Unique universal donor stem cells with minimal risk of rejection

TC BioPharm (TCB) is a biopharmaceutical business currently developing the closest to market drug candidate in Gamma Delta T (GDT) cell therapies. We have a strong focus on chimeric antigen receptor (CAR) modified GDT cells with the aim of treating cancer and major viral diseases.  We have a unique technology with a demonstrable safety profile and established intellectual property rights for the entire GDT-based platforms - ImmuniCAR® and OmmniCAR®.  This negates increasing concerns over the safety of current alpha beta CAR-T cell therapy approaches. Our proprietary culture media and manufacturing methods overcome the major barriers to commercialising GDT cell therapies, ensuring batch consistency.

We operate a GMP cell therapy manufacturing facility from headquarters near Glasgow. All regulatory, clinical and quality functions are performed in-house. We also have facilities in Edinburgh, London, and Kawasaki City (in the Greater Tokyo area).
Image
GDT cells are naturally-occurring cells within the human body, inducing one of the first lines of defence against infectious disease.  These cells are primed to attack and destroy ‘biologically-stressed’ cells: those either infected with virus/bacteria, or cancerous cells. They do this by detecting isopentenyl pyrophosphates (IPPs) on the surface of cells which have become stressed by transformation or infection.

We are creating ground breaking, pioneering, disruptive therapies with unrivalled applicability to a broad range of cancers and viral infections.  This step-changing approach leverages the immense therapeutic and commercial potential of GDT cells by ‘pharmaceuticalising’ cell therapy, simplifying its ease of use, widening patient access and improving Quality of Life.

TCB has a number of partnership and licensing opportunities across its product platforms.
Contact us for further information, including safety profiling and efficacy equivalence.

let's talk about how we can work together

Search